2. Academic Validation
  3. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

  • Bioorg Med Chem Lett. 2007 Mar 1;17(5):1250-3. doi: 10.1016/j.bmcl.2006.12.018.
Michael P Clark 1,  Kelly M George,  Roger G Bookland,  Jack Chen,  Steven K Laughlin,  Kumar D Thakur,  Wenlin Lee,  Jan R Davis,  Ed J Cabrera,  Todd A Brugel,  John C VanRens,  Matthew J Laufersweiler,  Jennifer A Maier,  Mark P Sabat,  Adam Golebiowski,  Vijay Easwaran,  Mark E Webster,  Biswanath De,  George Zhang
Affiliations

Affiliation

  • 1 Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040, USA. [email protected]
PMID: 17189692 DOI: 10.1016/j.bmcl.2006.12.018
Abstract

A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.

Figures